Amedisys saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 68 to 72.
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that identifies how a stock's price action over the last 52 weeks compares to other publicly traded companies.
Decades of market research reveals that the best stocks often have an 80 or better RS Rating as they launch their largest climbs. See if Amedisys can continue to rebound and clear that threshold.
Can You Really Time The Stock Market?
Amedisys is building a consolidation with a 98.95 buy point. See if the stock can clear the breakout price in volume at least 40% above average.
Amedisys posted 2% EPS growth in the latest quarterly report. Sales gains came in at 5%.
The company holds the No. 8 rank among its peers in the Medical-Outpatient/Home Care industry group. Encompass Health, Fresenius Medical Care and Pediatrix Medical are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
